Emerging treatments for ulcerative colitis: a systematic review

@article{Kokkinidis2017EmergingTF,
  title={Emerging treatments for ulcerative colitis: a systematic review},
  author={Damianos G. Kokkinidis and Eftychia E Bosdelekidou and Sotiria Maria Iliopoulou and A. Tassos and Pavlos Texakalidis and Konstantinos P. Economopoulos and Antonis A. Kousoulis},
  journal={Scandinavian Journal of Gastroenterology},
  year={2017},
  volume={52},
  pages={923 - 931}
}
Abstract Objectives: Various investigational medicinal products have been developed for ulcerative colitis (UC). Our aim was to systematically evaluate novel pharmacological therapeutic agents for the treatment of UC. Material and methods: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations were followed. A search of the medical literature was conducted in the MEDLINE database for original research papers published between 01 January 2010 and 31 October… 

Positioning therapies in ulcerative colitis.

  • S. DaneseG. FiorinoL. Peyrin-Biroulet
  • Biology, Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2020

ASSESMENT OF QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS

The hypothesis that patients with ulcerative colitis have reduced quality of life when compared to healthy individuals is confirmed.

Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification

This review focuses on the rapidly evolving proteomics and lipidomics technologies and their broad applicability to IBD studies; these range from investigations of immune-regulatory mechanisms and biomarker discovery to studies dissecting host–microbiome interactions and the role of intestinal epithelial cells.

[Gastrointestinal tract diseases induced by medications].

Gastrointestinal symptoms are common side effects of medical drugs. They are usually mild but sometimes require diagnostic endoscopy and histologic evaluation. Due to the rapidly increasing number of

Contemporary Medical Management of Acute Severe Ulcerative Colitis.

Important concepts and recent advances in the evaluation and medical management of adult and pediatric patients with acute severe ulcerative colitis are reviewed.

Periplaneta americana extract promotes intestinal mucosa repair of ulcerative colitis in rat 1

PA treatment had a significant healing effect on the OXZ-colitis model and significantly reduced the lesioned area, especially in the PA-40H groups, suggesting that Periplaneta americana extract may be a potential compound for the treatment of colonic lesions.

Anti-Inflammatory and Antioxidant Activities of the Methanolic Extract of Cyrtocarpa procera Bark Reduces the Severity of Ulcerative Colitis in a Chemically Induced Colitis Model

The C. procera methanolic extract displayed good antioxidant capacity, probably due to the presence of polyphenolic compounds, in particular the flavonoids that were identified, such as chrysin, naringenin, kaempferol, and catechin, which have been reported to have anti-inflammatory and antioxidant activities.

Traditional Bulgarian Dairy Products: Ethnic Foods with Health Benefits

This review emphasises the features of LAB starters and the autochthonous microflora, the biochemistry of dairy food production, and the approaches for achieving the fortification of the foods with prebiotics, bioactive peptides, and other metabolites with reported beneficial effects on human health.

Erkrankungen des Gastrointestinaltrakts unter medikamentöser Immunmodulation

ZusammenfassungNebenwirkungen von Medikamenten im Gastrointestinaltrakt sind zwar häufig, jedoch meist passager und wenig gefährdend. Bei nur wenigen schwerwiegenderen Verläufen wird eine Endoskopie

Erkrankungen des Gastrointestinaltrakts unter medikamentöser Immunmodulation

ZusammenfassungNebenwirkungen von Medikamenten im Gastrointestinaltrakt sind zwar häufig, jedoch meist passager und wenig gefährdend. Bei nur wenigen schwerwiegenderen Verläufen wird eine Endoskopie

References

SHOWING 1-10 OF 44 REFERENCES

Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose‐ranging Study

Vedolizumab demonstrated dose‐proportional pharmacokinetics and maximally saturated receptors on peripheral serum lymphocytes at all measurable serum concentrations over the tested dose range.

Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.

Golimumab (50 mg or 100 mg) maintained clinical response through week 54 in patients who responded to induction therapy with golimumab and had moderate-to-severe active ulcerative colitis; patients who received 100 mg Golimumab had clinical remission and mucosal healing at weeks 30 and 54.

Randomized clinical trial: Atorvastatin versus placebo in patients with acute exacerbation of mild to moderate ulcerative colitis

Atorvastatin therapy in acute exacerbation of UC may not be associated with beneficial effects and Paradoxical increase in disease activity may be seen in some patients, but these findings need to be substantiated in larger studies.

Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

Treatment with subcutaneous golimumab induces clinical response, remission, and mucosal healing, and increases quality of life in larger percentages of patients with active UC than placebo.

Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease

Vedolizumab every 8 weeks for up to 78 weeks had an adverse event profile similar to that previously observed and mean disease activity indices improved with all 3 doses investigated.

A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis

Tofacitinib monotherapy, or in combination with traditional DMARDs, has demonstrated its efficacy while having an acceptable safety profile in RA patients who have responded inadequately to current DMARDS, including TNF antagonists.

Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis

Visilizumab at a dose of 5 μg/kg for two consecutive days was not effective for severe, corticosteroid-refractory UC and was associated with increased cardiac and vascular adverse events.

Current approaches to the management of new-onset ulcerative colitis

The authors provide a comprehensive evidence-based approach to current treatment options for new-onset UC with discussion of long-term therapeutic efficacy and safety, patient-centered perspectives including quality of life and medication compliance, and future directions in related inflammatory bowel disease care.

Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis

Rituximab has no significant effect on inducing remission in moderately active UC not responding to oral steroids, and is well tolerated in UC.